GSK Links With Adaptimmune In Oncology Intracellular TCR R&D Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline has entered a long-term cell-based immunotherapy collaboration with T cell receptor specialist Adaptimmune, signaling the Big Pharma player is still investing in cutting-edge oncology R&D.